Association of asthma therapy and churg-strauss syndrome: An analysis of postmarketing surveillance data

Clinical Therapeutics

Volumn 26, Issue 7, 2004, Pages 1092-1104

  Dumouchel, William ^a,f   Smith, Eric T ^b   Beasley, Richard ^c   Nelson, Harold ^d   Yang, Xionghu ^e   Fram, David ^e   Almenoff, June S ^b  

^a AT AND T LABS RESEARCH   (United States)

^b GLAXOSMITHKLINE   (United States)

^c MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^d NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^e Lincoln Technologies   (United States)

^f NONE   (United States)

Author keywords

asthma; Churg Strauss; inhaled steroids; leukotriene receptor antagonists

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; SHORT ACTING DRUG;

ALGORITHM; ARTICLE; ASTHMA; BAYES THEOREM; CALCULATION; CHURG STRAUSS SYNDROME; CONTROLLED STUDY; DATA BASE; DRUG SAFETY; EXAMINATION; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMATION PROCESSING; OBSERVATION; POSTMARKETING SURVEILLANCE; UNITED STATES;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-ASTHMATIC AGENTS; ASTHMA; CHURG-STRAUSS SYNDROME; HUMANS; LEUKOTRIENE ANTAGONISTS; POLYPHARMACY; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 4344689546     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90181-6     Document Type: Article

References (33)

1. Churg J., Strauss L. Allergic granulomatosis, allergic angiitis and periarteritis nodosa. Am J Pathol. 27:1951;277-301
2. Churg A. Recent advances in the diagnosis of Churg-Strauss syndrome. Mod Pathol. 14:2001;1284-1293
3. Ramakrishna G., Midthun D.E. Churg-Strauss syndrome. Ann Allergy Asthma Immunol. 86:2001;605-613
4. Guillevin L., Cohen P., Gayraud M., et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 78:1999;26-37
5. Wechsler M.E., Pauwels R., Drazen J.M. Leukotriene modifiers and Churg-Strauss syndrome: Adverse effect or response to corticosteroid withdrawal? Drug Saf. 21:1999;241-251
6. Wechsler M.E., Finn D., Gunawardena D., et al. Churg-Strauss syndrome in patients receiving montelukas as treatment for asthma. Chest. 117:2000;708-713
7. Weller P.F., Plaut M., Taggart V., Trontell A. The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. J Allergy Clin Immunol. 108:2001;175-183
8. Guilpain P., Viallard J.F., Lagarde P., et al. Churg-Strauss syndrome in two patients receiving montelukast. Rheumatology (Oxford). 41:2002;535-539
9. Noth I., Strek M.E., Leff A.R. Churg-Strauss syndrome. Lancet. 361:2003;587-594
10. Martin R.M., Wilton L.V., Man R.D. Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: Retrospective analysis of 58 prescription-event monitoring cohort studies. Pharmacoepidemiol Drug Saf. 8:1999;179-189
11. Szarfman A., Machado S.G., O'Neill R.T. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. 25:2002;381-392
12. O'Neill R.T., Szarfman A. Some US Food and Drug Administration perspectives on data mining for pediatric safety assessment. Curr Ther Res Clin Exp. 62:2001;650-663
13. Evans S.J., Waller P.C., Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 10:2001;483-486
14. Coulter D.M., Bate A., Meyboom R.H., et al. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: Data mining study. BMJ. 322:2001;1207-1209
15. Bate A., Lindquist M., Edwards I.R., Orre R. A data mining approach for signal detection and analysis. Drug Saf. 25:2002;393-397
16. Goldkind L. Hepatotoxicity: Leflunomide (online). Available at: http://www.fda.gov/ohrms/dockets/ac/03/slides/3930S2_05_FDA-Goldkind.ppt.:June 4, 2004;. Accessed
17. Bate A., Lindquist M., Orre R., et al. Data-mining analyses of pharacovigilance signals in relation to relevant comparison drugs. Eur J Clin Pharmacol. 58:2002;483-490
18. Hedenmalm K., Hägg S., Ståhl M., et al. Glucose intolerance with atypical antipsychotics. Drug Saf. 25:2002;1107-1116
19. Hauben M., Zhou X. Quantitative methods in pharmacovigilance: Focus on signal detection. Drug Saf. 26:2003;159-186
20. van Puijenbroek E.P., Bate A., Leufkens H.G., et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 11:2002;3-10
21. Kennedy D., Goldman S.A., Lillie R.B. Spontaneous reporting in the United States. Strom B. Pharmacoepidemiology. 3rd ed. :2000;151-174 John Wiley & Sons, New York, NY
22. Trontell A.E. How the US Food and Drug Administration defines and detects adverse drug events. Curr Ther Res Clin Exp. 62:2001;641-649
23. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA Spontaneous Reporting System. The American Statistician. 53:1999;177-202
24. DuMouchel W., Pregibon D. Empirical Bayes screening for multi-item associations in massive database. The Sevent ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. San Francisco, Calif. :August 26-29, 2001
25. Wechsler M.E., Garpestad E., Flier S.R., et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA. 279:1998;455-457
26. Accolate (zafirlukast). 2001;AstraZeneca Pharmaceuticals LP, Wilmington, Del. [package insert]
27. Flovent (fluticasone propionate). 2001;GlaxoSmithKline, Research Triangle Park. [package insert]
28. Singulair (montelukast sodium). 2001;Merck & Co, Inc., Rahway, NJ. [package insert]
29. HHS/FDA/CDER. Data extract from the Adverse Event Reporting System (AERS). NTIS Order Number: SUB-5460.
30. Purcell P., Barty S. Statistical techniques for signal generation: The Australian experience. Drug Saf. 25:2002;415-421
31. Almenoff J.S., DuMouchel W., Kindman L.A., et al. Disproportionality analysis using empirical Bayes data mining: A tool for ethe evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiol Drug Saf. 12:2003;517-521
32. Almenoff J.S., DuMouchel W., Kindman L.A., et al. published correction appears in Pharmacoepidemiol Drug Saf. 13:2004;111
33. van der Heijden P.G., Puijenbroek E.P., van Buuren S., van de Hofstede J.W. On the assessment of adverse drug reactions from spontaneous reporting systems: The influence of under-reporting on odds ratios. Stat Med. 21:2002;2027-2044